Based on 4 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $22.00 with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 94.17% change from the last price of $11.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","23":"$23","8.75":"$8.75","13.5":"$13.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.75,13.5,18.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.37,13.11076923076923,13.85153846153846,14.592307692307692,15.333076923076923,16.073846153846155,16.814615384615387,17.555384615384614,18.296153846153846,19.036923076923078,19.777692307692305,20.518461538461537,21.25923076923077,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.37,13.11076923076923,13.85153846153846,14.592307692307692,15.333076923076923,16.073846153846155,16.814615384615387,17.555384615384614,18.296153846153846,19.036923076923078,19.777692307692305,20.518461538461537,21.25923076923077,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.37,13.11076923076923,13.85153846153846,14.592307692307692,15.333076923076923,16.073846153846155,16.814615384615387,17.555384615384614,18.296153846153846,19.036923076923078,19.777692307692305,20.518461538461537,21.25923076923077,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.51,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$22.00

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

01/13/25

Assigned

01/13/25

Assigned

12/24/24

Reiterated

12/11/24

xxxxxxxxxxxxx

Salim Syed

Mizuho Securities

$19→$22

Buy

94.17%

Upside

Reiterated

11/21/24

Wave Life Sciences price target raised to $22 from $19 at MizuhoWave Life Sciences price target raised to $22 from $19 at Mizuho

Eric Joseph

J.P. Morgan

$17→$20

Buy

76.52%

Upside

Reiterated

11/13/24

J.P. Morgan Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Andrew Fein

H.C. Wainwright

$22

Buy

94.17%

Upside

Reiterated

11/13/24

Wave Life Sciences Gains Buy Rating from Andrew Fein Amid Promising Trial Advancements and Potential Accelerated Approval Pathways

Catherine Novack

JonesTrading

$20

Buy

76.52%

Upside

Reiterated

11/12/24

We are bullish on WVE over the next 12-18 months, given multiple upcoming inflection points, and we think there's a lot of value to unlock in the RNA editing platform with expansion into more prevalent liver and metabolic diseases. Reiterate BUY $20 PT. 1) What are the gating factors to starting the HD pivotal program? The primary focus now is achieving regulatory alignment on caudate volume as a surrogate endpoint for accelerated approval. The pivotal study will be powered to show difference on CV and not clinical outcomes (see more on powering differences below). Management has noted that the FDA has expressed openness to recognizing new biomarkers in HD.There's readthrough to partnering discussions as well, since we expect that commercial partners will want to see clarity on the path forward before engaging.

Luca Issi

RBC Capital

$15

Hold

32.39%

Upside

Reiterated

11/12/24

RBC Capital Sticks to Their Hold Rating for Wave Life Sciences (WVE)

Steven Seedhouse

Raymond James

$22

Buy

94.17%

Upside

Reiterated

10/16/24

Wave Life Sciences upgraded to Strong Buy from Outperform at Raymond JamesWave Life Sciences upgraded to Strong Buy from Outperform at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

Which Analyst Should I Follow If I Want to Buy WVE and Sell After:

1 Month

xxx

Success Rate

7/14 ratings generated profit

Average Return

+8.39%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +8.39% per trade.

3 Months

xxx

Success Rate

22/50 ratings generated profit

Average Return

+0.98%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.00% of your transactions generating a profit, with an average return of +0.98% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

11/14 ratings generated profit

Average Return

+58.95%

reiterated a buy rating 3 months ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +58.95% per trade.

2 Years

xxx

Success Rate

12/14 ratings generated profit

Average Return

+115.39%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +115.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WVE Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Dec 24

Jan 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WVE has received 18 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WVE average Analyst price target in the past 3 months is $22.00.

Each month's total comprises the sum of three months' worth of ratings.

WVE Financial Forecast

WVE Earnings Forecast

Next quarter’s earnings estimate for WVE is -$0.19 with a range of -$0.40 to $0.10. The previous quarter’s EPS was -$0.47. WVE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 31.58% of the time in the same period. In the last calendar year WVE has Outperformed its overall industry.

WVE Sales Forecast

Next quarter’s sales forecast for WVE is $27.54M with a range of $1.76M to $70.20M. The previous quarter’s sales results were -$7.68M. WVE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year WVE has Outperformed its overall industry.

WVE Stock Forecast FAQ

What is WVE’s average 12-month price target, according to analysts?

Based on analyst ratings, Wave Life Sciences’s 12-month average price target is $22.00.

What is WVE’s upside potential, based on the analysts’ average price target?

Wave Life Sciences has 94.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WVE a Buy, Sell or Hold?

Wave Life Sciences has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Wave Life Sciences’s price target?

The average price target for Wave Life Sciences is $22.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $22.00. The average price target represents 94.17% Increase from the current price of $11.33.

What do analysts say about Wave Life Sciences?

Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of WVE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wave Life Sciences (WVE) Stock Forecast & Price Target

WVE Analyst Ratings

WVE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wave Life Sciences

WVE Analyst Recommendation Trends

WVE Financial Forecast

WVE Earnings Forecast

WVE Sales Forecast

WVE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts